Niagen Bioscience, Inc. Common Stock NAGE Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $31.47M-7.0% | $33.84M-0.4% | $33.99M+9.2% | $31.12M+2.1% | $30.48M+4.7% | ||
| $11.5M-5.2% | $12.14M+0.6% | $12.06M+10.7% | $10.89M-2.3% | $11.15M+2.0% | ||
| $19.98M-8.0% | $21.7M-1.0% | $21.93M+8.4% | $20.23M+4.6% | $19.33M+6.2% | ||
| 63.5%-0.7pp | 64.1%-0.4pp | 64.5%-0.5pp | 65%+1.6pp | 63.4%+0.9pp | ||
| $1.48M-13.4% | $1.71M-4.7% | $1.8M+14.6% | $1.57M+24.6% | $1.26M-4.3% | ||
| $9.68M-7.1% | $10.41M+18.8% | $8.77M+6.8% | $8.21M+1.1% | $8.12M-6.9% | ||
| $7.24M-3.1% | $7.48M+4.9% | $7.13M-1.9% | $7.27M+40.2% | $5.18M+391% | ||
| $18.4M+4.4% | $17.62M-0.4% | $17.69M+3.8% | $17.04M+17.0% | $14.56M+31.3% | ||
| $1.58M-61.4% | $4.09M-3.5% | $4.24M+33.0% | $3.19M-33.3% | $4.77M-32.9% | ||
| 5%-7.1pp | 12.1%-0.4pp | 12.5%+2.2pp | 10.2%-5.4pp | 15.7%-8.8pp | ||
| $375K+10.9% | $338K-40.1% | $564K+2.2% | $552K+20.3% | $459K+23.1% | ||
| $6.74M+52.2% | $4.42M-7.8% | $4.8M+28.4% | $3.74M-28.6% | $5.23M-30.1% | ||
| $417K+42.8% | $292K+31.5% | $222K+73.4% | $128K-23.8% | $168K-44.9% | ||
| $6.32M+52.9% | $4.13M-9.7% | $4.58M+26.8% | $3.61M-28.7% | $5.06M-29.5% | ||
| 20.1%+7.9pp | 12.2%-1.3pp | 13.5%+1.9pp | 11.6%-5.0pp | 16.6%-8.0pp | ||
| $0.07+40.0% | $0.050.0% | $0.05+25.0% | $0.04-33.3% | $0.06-33.3% | ||
| $1.87M-56.4% | $4.29M-3.3% | $4.43M+31.1% | $3.38M-31.9% | $4.97M-32.0% | ||
| 5.9%-6.7pp | 12.7%-0.4pp | 13%+2.2pp | 10.9%-5.4pp | 16.3%-8.8pp | ||
| $1.58M-61.4% | $4.09M-3.5% | $4.24M+33.0% | $3.19M-33.3% | $4.77M-32.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Niagen Bioscience, Inc. Common Stock's revenue?
- Niagen Bioscience, Inc. Common Stock (NAGE) generated $130.4M in revenue over the trailing twelve months, up 20.8% year over year.
- Is Niagen Bioscience, Inc. Common Stock profitable?
- Niagen Bioscience, Inc. Common Stock reported $18.6M in net income over the trailing twelve months, a 14.3% net margin.
- What are Niagen Bioscience, Inc. Common Stock's profit margins?
- Gross margin is 64.3% and operating margin is 10.0%, with a 14.3% net margin.
- What is Niagen Bioscience, Inc. Common Stock's earnings per share?
- Niagen Bioscience, Inc. Common Stock's diluted EPS over the trailing twelve months is $0.21.
- Where does Niagen Bioscience, Inc. Common Stock's income statement data come from?
- Every line is extracted from Niagen Bioscience, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
